000			nab a22 7a 4500
999			_c17998 _d17998
003			PC17998
005			20250616135531.0
008			250616b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_92616 _aLópez Muñoz, Francisco _eInstituto de Investigación i+12
245	0	0	_aMelatonin and Nitrones As Potential Therapeutic Agents for Stroke. _h[artículo]
260			_bFrontiers in aging neuroscience, _c2016
300			_a9:159.
500			_aFormato Vancouver: Romero A, Ramos E, Patiño P, Oset Gasque MJ, López Muñoz F, Marco Contelles J et al. Melatonin and Nitrones As Potential Therapeutic Agents for Stroke. Front Aging Neurosci. 2016 Nov 23;8:281. doi: 10.3389/fnagi.2016.00281. Erratum in: Front Aging Neurosci. 2017 May 29;9:159.
501			_aPMID: 27932976 PMC5120103
504			_aContiene 102 referencias
505			_aCorrigendum: Melatonin and Nitrones As Potential Therapeutic Agents for Stroke. PMID: 28572769
520			_aStroke is a disease of aging affecting millions of people worldwide, and recombinant tissue-type plasminogen activator (r-tPA) is the only treatment approved. However, r-tPA has a low therapeutic window and secondary effects which limit its beneficial outcome, urging thus the search for new more efficient therapies. Among them, neuroprotection based on melatonin or nitrones, as free radical traps, have arisen as drug candidates due to their strong antioxidant power. In this Perspective article, an update on the specific results of the melatonin and several new nitrones are presented.
710			_9625 _aInstituto de Investigación imas12
856			_uhttps://pmc.ncbi.nlm.nih.gov/articles/PMC5120103/pdf/fnagi-08-00281.pdf _yAcceso libre
942			_2ddc _cART _n0